论文部分内容阅读
目的:评价多西他赛联合替吉奥胶囊治疗一线用药失败后复发转移性乳腺癌患者的近期疗效及安全性。方法:采用以下方案:多西他赛75 mg.m-2,静脉滴注1 h,第1天;替吉奥胶囊60 mg,2次.d-1,第1～14天;21 d为1个周期,治疗2个周期评价疗效及安全性。结果:21例患者均可评价疗效,其中完全缓解(CR)1例,部分缓解(PR)10例,病情稳定5例,病情进展5例,有效率(CR+PR)为52.4%,疾病控制率为76.2%。不良反应主要表现为骨髓抑制、胃肠道反应、脱发和手足综合征,均可耐受。结论:多西他赛联合替吉奥胶囊治疗复发转移性乳腺癌,能够明显延长患者生存时间并且提高治疗效果,且毒副作用小,作为复发转移性乳腺癌二线维持治疗值得临床推广。
OBJECTIVE: To evaluate the short-term efficacy and safety of docetaxel in combination with tigiao capsule in the treatment of patients with recurrent metastatic breast cancer after first-line failure. Methods: The following scheme was adopted: Docetaxel 75 mg.m-2 was given intravenously for 1 h on the first day, while for the Gio capsules 60 mg twice daily for days 1 to 14 and for 21 d 1 cycle, treatment of 2 cycles evaluation of efficacy and safety. Results: All of the 21 patients were evaluated for their efficacy. Among them, 1 was complete remission (CR), 10 were partial remission (PR), 5 were stable, 5 were progression. The response rate was 52.4% The rate was 76.2%. Adverse reactions mainly manifested as bone marrow suppression, gastrointestinal reactions, hair loss and hand-foot syndrome, can be tolerated. CONCLUSION: Docetaxel combined with tigeorgang capsule in the treatment of recurrent metastatic breast cancer can prolong the survival time and improve the curative effect of the patients with less side effects.